Obio Technology (Shanghai) Corp., Ltd. (688238.SS)

5.96 -0.24 (-3.87%) At close: 03:00PM CST

Obio Technology (Shanghai) Corp., Ltd.

Building 19
Lane 908, Ziping Road International Medical Park Pudong New Area
Shanghai 201321
China
86 21 5858 5887
https://www.obiosh.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Oudong Pan	Founder & Chairman of the Board	N/A	N/A	1968
Mr. Guodong Jia Ph.D.	GM & Director	N/A	N/A	1981
Mr. Junyi Pan	Investment Director & Director	N/A	N/A	1994
Ms. Qingmei Xia	Vice President of Human Resources & Commercial Management	N/A	N/A	1979
Mr. Fujie Wang	VP of Supply Chain & Information Technology and Director	N/A	N/A	1975
Ms. Shan Yin	Deputy GM & Director	N/A	N/A	1982
Mr. Xinglin Yang	R & D Director	N/A	N/A	1976
Ms. Luyuan Xu	Deputy GM, CFO & Board Secretary	N/A	N/A	1970
Qinbin Wu	Chief Quality Officer	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Obio Technology (Shanghai) Corp., Ltd., a biotechnology company, focuses on the development of gene therapy vectors in China. The company provides gene function and gene therapy research, and other CRO services, such as drug target and drug efficacy research. It also offers CDMO services, such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs. The company was founded in 2013 and is headquartered in Shanghai, China.

Corporate governance

Obio Technology (Shanghai) Corp., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.